Sanne Holt, PhD

Sanne Holt, PhD

Group Leader

Dr. Sanne Holt is the Group Leader at our site in Leiden, The Netherlands. Her research focuses on efficacy and toxicity testing of novel drug therapies in human primary cell-based models. She previously worked as an investigator within the Cell and Gene Therapy Unit for GlaxoSmithKline, where she focused on the translational and safety aspects of T cell therapies.

Dr. Holt holds an MRes and PhD in medical and molecular genetics from King’s College London.